Brokerages expect Iterum Therapeutics PLC (NASDAQ:ITRM) to announce earnings of ($1.62) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Iterum Therapeutics’ earnings. Iterum Therapeutics reported earnings per share of ($2.22) in the same quarter last year, which would indicate a positive year over year growth rate of 27%. The business is expected to report its next quarterly earnings results on Tuesday, August 13th.
On average, analysts expect that Iterum Therapeutics will report full year earnings of ($6.48) per share for the current financial year, with EPS estimates ranging from ($6.95) to ($6.01). For the next fiscal year, analysts expect that the business will post earnings of ($3.88) per share, with EPS estimates ranging from ($4.95) to ($2.81). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Iterum Therapeutics.
Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.09). The firm had revenue of $0.04 million during the quarter. Iterum Therapeutics had a negative net margin of 11,956.64% and a negative return on equity of 83.95%.
Shares of ITRM opened at $6.45 on Thursday. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.24. Iterum Therapeutics has a 12 month low of $4.70 and a 12 month high of $13.00.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.